ADAM COHEN to Male
This is a "connection" page, showing publications ADAM COHEN has written about Male.
Connection Strength
0.238
-
Persistent Genital Arousal and Major Depressive Disorder in an Adolescent Male: Case Report and Discussion. Urology. 2021 11; 157:239-241.
Score: 0.029
-
Full-Body Rash and Fever in a 15-Year-Old Male. Clin Pediatr (Phila). 2020 09; 59(9-10):933-937.
Score: 0.026
-
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019 03 20; 9(4):37.
Score: 0.025
-
Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine-Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma. Cancer Immunol Res. 2019 04; 7(4):658-669.
Score: 0.025
-
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018 12; 19(12):1641-1653.
Score: 0.024
-
Risk Factors and Outcomes After a Brief Resolved Unexplained Event: A Multicenter Study. Pediatrics. 2021 07; 148(1).
Score: 0.014
-
Long-Term (=5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2025 Sep; 43(25):2766-2771.
Score: 0.009
-
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat Med. 2025 Apr; 31(4):1134-1144.
Score: 0.009
-
The effect of a provisional diagnosis on intern diagnostic reasoning: a mixed methods study. Diagnosis (Berl). 2025 May 01; 12(2):208-216.
Score: 0.009
-
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. Lancet Haematol. 2022 Dec; 9(12):e897-e905.
Score: 0.008
-
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021 07 24; 398(10297):314-324.
Score: 0.007
-
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer J. 2020 10 23; 10(10):106.
Score: 0.007
-
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020 10; 21(10):1317-1330.
Score: 0.007
-
Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma. Clin Cancer Res. 2020 08 01; 26(15):3969-3978.
Score: 0.007
-
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest. 2019 08 13; 129(10):4451-4463.
Score: 0.006
-
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma. Cancer. 2017 Dec 01; 123(23):4617-4630.
Score: 0.006
-
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017 08 03; 130(5):597-605.
Score: 0.005
-
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2016 Dec 01; 22(23):5688-5695.
Score: 0.005
-
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015 Nov 12; 126(20):2284-90.
Score: 0.005
-
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2015 Sep 15; 21(18):4055-61.
Score: 0.005